Effects of lidocaine and mexiletine on defibrillation energy requirements in animals treated with flecainide

Resuscitation

Volumn 36, Issue 3, 1998, Pages 175-180

  Sato, Shigehito ^a   Imagawa, Naoya ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Antiarrhythmic drugs; Flecainide; Lidocaine; Mexiletine; Ventricular defibrillation threshold (DFT)

Indexed keywords

ANTIARRHYTHMIC AGENT; ENCAINIDE; FLECAINIDE; LIDOCAINE; MEXILETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEFIBRILLATION; DOG; DRUG BLOOD LEVEL; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; SUDDEN DEATH; TIME;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOGS; ELECTRIC COUNTERSHOCK; FLECAINIDE; LIDOCAINE; MEXILETINE; VENTRICULAR FIBRILLATION;

EID: 0032032670     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9572(98)00024-0     Document Type: Article

References (24)

1. [1] Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Green HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial. New Engl J Med 1991;324:781-8.
2. [2] Jung W, Manz M, Pizzulli L, Pfeiffer D, Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992;70:1023-7.
3. [3] Fain ES, Dorian P, Davy JM, Kates RE, Winkle RA. Effects of encainide and its metabolises on energy requirements for defibrillation. Circulation 1986;73:1334-41.
4. [4] Wehr M, Noll B, Krappe J. Flecainide induced aggravation of ventricular arrhythmias. Am J Cardiol 1985;55:1643-4.
5. [5] Dorian P, Fain ES, Davy JM. Lidocaine causes a reversible, concentration dependent increase in defibrillation energy requirements. J Am Coll Cardiol 1986;8:327-32.
6. [6] Marinchak RA, Friehling TD, Kline RA, Stohler J, Kowery PR. Effect of antiarrythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature. PACE 1988;11:7-12.
7. [7] Hernandez R, Mann DE, Breckinridge S, Williams GR, Reiter MJ. Effects of flecainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol 1989;14:777-81.
8. [8] Brugada J, Boersma L, Kirchhof C, Allessie M. Proarrhythmic effects of flecainide. Circulation 1991;84:1808-18.
9. [9] Sato S, Tsuji MH, Naito H. Mexiletine has no effect on defibrillation energy requirements in dogs. Pacing Clin Electrophysiol 1994;17:2279-84.
10. [10] Benet LZ, Williams RL. Pharmacokinetic data. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The Pharmacological Basis of Therapeutics. 8th ed. Oxford: Pergamon Press, 1990: 1688-92.
11. [11] Murakawa Y, Toda I, Nozaki A, Kawakubo K, Sugimoto T. Effects of antiarrhythmic drugs on the repetitive extrasystole threshold and the ventricular fibrillation threshold. Cardiology 1989;76:58-66.
12. [12] Usui M, Inoue H, Saihara S, Sugimoto T. Antifibrillatory effects of Class III antiarrhythmic drugs: comparative study with flecainide. J Cardiovasc Pharmacol 1993;21:376-83.
13. [13] Euler DE, Scanlon PJ. Comparative effects of antiarrhythmic drugs on the ventricular fibrillation threshold. J Cardiovasc Pharmacol 1988;11:291-8.
14. [14] Hernandez R, Mann DE, Breckinridge S, Williams GR, Reiter MJ. Effects of flecainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol 1989;14:777-81.
15. [15] Ujhelyi MR, O'Rangers EA, Kluger J, Fan C, Chow M. Defibrillation energy requirements during moricizine and moricizine-lidocaine therapy. J Cardiovasc Pharmacol 1992;20:932-9.
16. [16] Kerber RE, Pandian NG, Jensen SR, Constantine L, Kieso RA, Melton J, Hunt M. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: experimental studies. J Am Coll Cardiol 1986;7:397-405.
17. [17] Jones DL, Klein GJ, Guiraudon GM, et al. Effects of lidocaine and verapamil on defibrillation in humans. J Electrocardiol 1991;24:299-305.
18. [18] Babbs CF, Yim GKW, Whistler SJ, Tacker WA, Geddes LA. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs. Am Heart J 1979;98:345-50.
19. [19] Ujhelyi MR, Schur M, Frede T, Markel ML. Differential effects of lidocaine on defibrillation threshold with monophasic versus biphasic shock waveforms. Circulation 1995;92:1644-50.
20. [20] Echt DS, Gremillion ST, Lee JT, Roden DM, Murray KT, Borganelli M, Crawford DM, Stewart JR, Hammon JW. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillation devices. J Cardiovasc Electrophysiol 1994;5:752-60.
21. [22] Ruffy R, Schechtman K, Monje E, Sandza J. Adrenergically mediated variations in the energy required to defibrillate the heart: observations in closed-chest, nonanesthetized dogs. Circulation 1986;73:374-80.
22. + concentrations. J Electrocardiol 1980;13:73-8.
23. [24] Grant AO, Trantham JL, Brown KK, Strauss HC. pH dependent effects of quinidine on the kinetics of dV/dt-max. Circ Res 1982;50:210-7.
24. [25] Babbs CF. Effect of pentobarbital anesthesia on ventricular defibrillation threshold in dogs. Am Heart J 1978;95:331-7.